Northwire Canada EditionFriday, October 16, 2026
Northwire
⌕
GOLD 4180.70 +0.2% SILVER 57.37 +0.4% COPPER 6.56 +0.1% OIL 98.60 +0.6% PALLADIUM 1116.25 −1.1% MON 0.385 −6.1% OMI 0.250 +0.0% BUFF 0.800 +2.6% FEO 0.650 +0.0% LIB 0.700 −2.8% NPR 0.640 +3.2% QZM 0.380 +0.0% BVA 0.750 −1.3% ONAU 0.530 +1.9% FMR 0.225 +0.0% GSVR 0.352 +3.7% PHNM 0.345 +1.5% SLG 5.66 −1.0% CASA 0.065 +8.3% DRY 0.220 +2.3% SOMA 0.560 +0.0% GOLD 4180.70 +0.2% SILVER 57.37 +0.4% COPPER 6.56 +0.1% OIL 98.60 +0.6% PALLADIUM 1116.25 −1.1% MON 0.385 −6.1% OMI 0.250 +0.0% BUFF 0.800 +2.6% FEO 0.650 +0.0% LIB 0.700 −2.8% NPR 0.640 +3.2% QZM 0.380 +0.0% BVA 0.750 −1.3% ONAU 0.530 +1.9% FMR 0.225 +0.0% GSVR 0.352 +3.7% PHNM 0.345 +1.5% SLG 5.66 −1.0% CASA 0.065 +8.3% DRY 0.220 +2.3% SOMA 0.560 +0.0%
Earnings

FLUENT Reports Third Quarter 2025 Results

FNT · Price

Executive Summary

  • FLUENT Corp. reported Q3 2025 revenue of $26.0 M, essentially flat YoY, but gross profit fell sharply to $8.0 M (31% of revenue) from $14.3 M (54.6%) a year earlier.
  • Adjusted EBITDA collapsed to $2.8 M from $7.5 M in Q3 2024; net loss widened to $13.6 M for the quarter and $32.0 M for the nine‑month period.
  • Management highlighted operational challenges (margin pressure, extraction inefficiencies) but noted progress on new indoor cultivation capacity in Florida (Rosa) and New York (Buffalo), with additional dispensary openings planned.

Key Details

  • Revenue: $26.0 M vs. $26.1 M YoY; Florida segment $21.6 M vs. $22.0 M YoY.
  • Gross Profit (pre‑fair‑value): $8.0 M (31% of revenue) vs. $14.3 M (54.6%) YoY.
  • Adjusted EBITDA: $2.8 M vs. $7.5 M YoY.
  • Cash Flow from Operations: Used $0.8 M vs. provided $9.5 M YoY.
  • Balance Sheet (30 Sep 2025): Cash & cash equivalents $15.1 M; total debt $72.2 M; common shares (as‑converted) 714 M vs. 342 M YoY.
  • Operational Highlights – Florida: Closed five low‑performing dispensaries, opened new Brandon store (total 31 stores); Rosa indoor facility completed first harvests; launched “Bag‑O 7g” ground flower statewide.
  • Operational Highlights – New York: Buffalo indoor facility nearing full operation; launch of Connected and Alien Labs SKUs in Dec 2025 (9 Alien Labs, 11 Connected strains). Rebranding of Manhattan/White Plains/Kingston dispensaries completed; Syracuse medical‑only store closed, new medical location planned for 2026.
  • Operational Highlights – Texas: Houston Education & Pick‑Up Center slated to open Dec 2025; RSO and distillate syringe production underway with additional SKUs in development.
  • Regulatory Outlook: Federal move to close hemp‑derived THC loophole expected to reduce illicit competition, potentially improving margins in Florida and Texas.
  • Management Commentary: Interim CEO Dave Vautrin emphasized focus on margin recovery via indoor capacity ramp‑up, product mix optimization, and disciplined market investments.
  • Conference Call: No earnings call will be hosted for the quarter.

Notable Quotes

“During the third quarter, we continued to execute on our strategic priorities with a clear focus on reversing the declining margin profile and enhancing operational efficiency… ” – Dave Vautrin, Interim CEO


Materiality Assessment: Material – Negative (significant decline in profitability and cash generation, coupled with forward‑looking statements about margin recovery).

Read the original news release →

More from None